Evidence map›Paper›PMID 42099067›Full record

ArticlemAbs2026

A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in human.

Monika Gajewska, Michael Kiffe, Claudio Calonder, Volker Engelhardt, Carla Pou I Miralbell, Elena Gonzalo-Gil, Gregory Christianson, Nijaguna Bethur, Adriano Flora

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Monika GajewskaNovartis AG, PK Sciences, Translational Medicine, BioMedical Research, Basel, Switzerland.
Michael KiffeNovartis AG, PK Sciences, Translational Medicine, BioMedical Research, Basel, Switzerland.
Claudio CalonderNovartis AG, PK Sciences, Translational Medicine, BioMedical Research, Basel, Switzerland.
Volker EngelhardtNovartis AG, PK Sciences, Translational Medicine, BioMedical Research, Basel, Switzerland.
Carla Pou I MiralbellNovartis AG, PK Sciences, Translational Medicine, BioMedical Research, Basel, Switzerland.
Elena Gonzalo-GilThe Jackson Laboratory, Preclinical Services, Gainesville, FL, USA.
Gregory ChristiansonThe Jackson Laboratory, JMCRS, Bar Harbor, ME, USA.
Nijaguna BethurThe Jackson Laboratory, JMCRS, Bar Harbor, ME, USA.
Adriano FloraThe Jackson Laboratory, JMCRS, Bar Harbor, ME, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we present a comprehensive evaluation of two human FcRn transgenic mouse models, Tg276 and Tg32, demonstrating their ability to predict the pharmacokinetic (PK) parameters of IgG-type antibodies in human and monkey (non-human primate, NHP), including molecules with and without half-life extension. To assess the translational relevance of the humanized FcRn mouse models, we integrated a broad dataset comprising

Indexed as

Antibodies, MonoclonalHistocompatibility Antigens Class IImmunoglobulin GReceptors, FcAnimalsHumansMiceMice, TransgenicAntibodies, MonoclonalFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin GReceptors, FcAllometric scalingFc-engineered antibodiesFcRnmonkeynon-human primatepharmacokineticsTg276Tg32

Identifiers

PMID42099067
PMCPMC13166230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.